Results for tag: "Metastatic Pancreatic Cancer Drug"

The Metastatic Pancreatic Cancer Drug market is a subset of the larger Pancreatic Cancer Drugs market. It is composed of drugs specifically designed to treat metastatic pancreatic cancer, which is cancer that has spread from the pancreas to other parts of the body. These drugs are typically used in combination with other treatments such as chemotherapy and radiation therapy. Commonly used drugs in this market include gemcitabine, capecitabine, and nab-paclitaxel. The Metastatic Pancreatic Cancer Drug market is highly competitive, with many companies vying for market share. Some of the major players in this market include Bristol-Myers Squibb, Celgene, Merck, Pfizer, and Roche. Other companies such as AbbVie, AstraZeneca, and Novartis also have a presence in this market. Show Less Read more